I-Mab announced that enrollment in the planned Phase 1b dose expansion cohorts for its givastomig combination study has been completed ahead of expectations. This study is evaluating givastomig in combination with immunochemotherapy in patients with first-line gastric cancers.
The accelerated enrollment reflects strong operational execution and continued momentum in the clinical development of givastomig, I-Mab's lead precision immuno-oncology agent. This progress follows the positive Phase 1b dose escalation data presented at ESMO GI on July 2nd.
With enrollment now complete, I-Mab anticipates providing topline results from the Phase 1b dose expansion study in the first quarter of 2026. This milestone brings the company closer to further validating givastomig's potential in a significant oncology indication.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.